

ASX Announcement

For immediate release

23rd August 2017

Bluechiip Appoints Blair Healy as Non-Executive Director

Bluechiip Limited [ASX: BCT], a leader in the development of sample tracking technology for harsh environments, today announced the appointment of Blair Healy as non-executive director, effective immediately.

Blair Healy has spent the past 17 years establishing, growing and selling technology companies, both publicly and privately. After graduating from the Royal Military College, Duntroon, Blair served in the Australian Army for 8 years in various technical and command positions. He was then a systems engineering consultant in several large defence and public transport projects. He worked for Futjitsu Telecommunications (R&D Manager) and Canada's Nortel Networks (Director Business Development & Operations Asia Pacific in Singapore) and was CEO of KUSP Limited until its sale to Senetas, and Innovonics Limited, which was sold to private US company Integrian. Between 2008 and 2013 he was founder and Managing Director of private company Cogent Energy, Australia's first low carbon distributed co-generation energy company, which was acquired by Origin Energy, and then Managing Director of Maxx Engineering, a private mechanical engineering services company which was sold to Thyssen Krupp in 2015.

lain Kirkwood, Bluechiip Limited Chairman, said: "Blair's technical and entrepreneurial experience is an excellent fit for our board. His appointment follows that of Andrew Cox last month and we are delighted these highly qualified, successful businessmen have joined us at this exciting phase of Bluechiip's rapid commercial growth."

END

For more information contact

Andrew McLellan Managing Director / CEO Ph: +61 457 823 470 andrew.mclellan@bluechiip.com

Media

Richard Allen Ph: +61 3 9915 6341 Oxygen Financial PR



ASX Announcement

For immediate release

23rd August 2017

About Bluechiip Limited

Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip® technology does not. Unlike labels, barcodes and RFID, the bluechiip® technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip® technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip® offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip® tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip® technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at www.bluechiip.com